- Home
- IBIO vs POAI Comparison
IBIO vs POAI Comparison
Compare IBIO & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- POAI
- Stock Information
- Founded
- IBIO 2008
- POAI 2002
- Country
- IBIO United States
- POAI United States
- Employees
- IBIO N/A
- POAI N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- IBIO Health Care
- POAI Health Care
- Exchange
- IBIO Nasdaq
- POAI Nasdaq
- Market Cap
- IBIO 9.3M
- POAI 8.9M
- IPO Year
- IBIO N/A
- POAI N/A
- Fundamental
- Price
- IBIO $0.73
- POAI $1.10
- Analyst Decision
- IBIO Strong Buy
- POAI Hold
- Analyst Count
- IBIO 3
- POAI 1
- Target Price
- IBIO $4.87
- POAI N/A
- AVG Volume (30 Days)
- IBIO 2.3M
- POAI 82.2K
- Earning Date
- IBIO 05-02-2025
- POAI 05-15-2025
- Dividend Yield
- IBIO N/A
- POAI N/A
- EPS Growth
- IBIO N/A
- POAI N/A
- EPS
- IBIO N/A
- POAI N/A
- Revenue
- IBIO $375,000.00
- POAI $1,623,817.00
- Revenue This Year
- IBIO $36.00
- POAI $486.27
- Revenue Next Year
- IBIO N/A
- POAI $65.50
- P/E Ratio
- IBIO N/A
- POAI N/A
- Revenue Growth
- IBIO 650.00
- POAI N/A
- 52 Week Low
- IBIO $0.64
- POAI $0.55
- 52 Week High
- IBIO $6.89
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- IBIO 24.07
- POAI 50.57
- Support Level
- IBIO $0.75
- POAI $0.85
- Resistance Level
- IBIO $0.82
- POAI $1.19
- Average True Range (ATR)
- IBIO 0.14
- POAI 0.09
- MACD
- IBIO 0.10
- POAI 0.01
- Stochastic Oscillator
- IBIO 3.04
- POAI 42.74
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.